Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.

International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV / S. Singer, C.D. Amdal, E. Hammerlid, I.M. Tomaszewska, J. Castro Silva, H. Mehanna, M. Santos, J. Inhestern, C. Brannan, N. Yarom, A. Fullerton, M. Pinto, J.I. Arraras, N. Kiyota, P. Bonomo, A.C. Sherman, I. Baumann, R. Galalae, L. Fernandez Gonzalez, O. Nicolatou-Galitis, Z. Abdel-Hafeez, J. Raber-Durlacher, C. Schmalz, P. Zotti, A. Boehm, D. Hofmeister, S. Krejovic Trivic, S. Loo, W. Chie, K. Bjordal, B. Brokstad Herlofson, V. Grégoire, L. Licitra. - In: HEAD & NECK. - ISSN 1043-3074. - (2019 Jan 12). [Epub ahead of print]

International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV

L. Licitra
2019

Abstract

Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.
chemoradiation; head and neck cancer; multimodal therapies; quality of life; validation;
Settore MED/06 - Oncologia Medica
12-gen-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
Singer_et_al-2019.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.01 MB
Formato Adobe PDF
1.01 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/612202
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 57
  • ???jsp.display-item.citation.isi??? 58
social impact